---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-286070"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2021-09-29T23:59:59+00:00"
generated_at: "2026-06-29T00:44:27.107641+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences reports improved pulmonary function in DMD gene therapy trial, controls decline

## Summary
- PEF % predicted improved in all 4 evaluable dosed patients (+2.5% to +38.5%); 2 evaluable controls declined (-1.1%, -18.2%) at one year.
- FEV1 % predicted improved in all 5 evaluable dosed patients (+2.8% to +15.5%); all 3 evaluable controls declined (-8.7% to -17.0%).
- Data from first 6 patients in Phase I/II IGNITE DMD trial of SGT-001; presented at Child Neurology Society 50th Annual Meeting.

## SEC filing metadata
- accession: 0001193125-21-286070
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2021-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312521286070/0001193125-21-286070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312521286070/d230511d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-286070
- JSON: https://secwatch.observer/filing/0001193125-21-286070.json
- Plain text: https://secwatch.observer/filing/0001193125-21-286070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.